Northern Trust
APGE icon

Northern Trust’s Apogee Therapeutics APGE Stock Holding History

Northern Trust’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$32.9M Buy
390,879
+63,503
+19% +$4.61M ﹤0.01% 1375
2025
Q4 		$24.7M Buy
327,376
+42,893
+15% +$2.7M ﹤0.01% 1531
2025
Q3 		$11.3M Buy
284,483
+20,295
+8% +$775K ﹤0.01% 2042
2025
Q2 		$11.5M Sell
264,188
-50,290
-16% -$1.91M ﹤0.01% 1988
2025
Q1 		$11.7M Sell
314,478
-12,814
-4% -$495K ﹤0.01% 1942
2024
Q4 		$14.8M Buy
327,292
+20,743
+7% +$1.06M ﹤0.01% 1888
2024
Q3 		$18M Sell
306,549
-4,654
-1% -$223K ﹤0.01% 1683
2024
Q2 		$12.2M Sell
311,203
-13,021
-4% -$632K ﹤0.01% 1877
2024
Q1 		$21.5M Buy
324,224
+147,451
+83% +$6.44M ﹤0.01% 1544
2023
Q4 		$4.94M Buy
176,773
+15,635
+10% +$313K ﹤0.01% 2529
2023
Q3 		$3.43M Buy
+161,138
New +$3.55M ﹤0.01% 2657

Other funds holding APGE

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Northern Trust's APGE Position: Q1 2026 in Review

Northern Trust increased its Apogee Therapeutics (APGE) stake by 19% in Q1 2026, buying an estimated $4.61M and bringing the position to 390,879 shares worth $32.9M. The position accounts for ﹤0.01% of the portfolio, ranked #1375.

Northern Trust first reported a position in APGE in Q3 2023 and has held it in 11 quarters since. 224 funds tracked by Wall St. Rank hold APGE as of Q1 2026.

  • Northern Trust held 390,879 shares of Apogee Therapeutics worth $32.9M as of Q1 2026.
  • Northern Trust bought 63,503 Apogee Therapeutics shares in Q1 2026, an estimated $4.61M.
  • Apogee Therapeutics made up ﹤0.01% of Northern Trust's portfolio in Q1 2026, its #1375 holding.
  • Northern Trust first reported a position in Apogee Therapeutics in Q3 2023 and has held it in 11 quarters since.
  • 224 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q1 2026.

Based on Northern Trust's 13F filing for Q1 2026, filed 14 May 2026.